

## VULVA STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS	PATHOLOGIC <i>Extent of disease during and from surgery</i>																																																																	
<input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	<b>TUMOR SIZE:</b> _____ <b>LATERALITY:</b> <input type="checkbox"/> left <input type="checkbox"/> right <input type="checkbox"/> bilateral	<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery																																																																	
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">PRIMARY TUMOR (T)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> TX</td> <td></td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td><input type="checkbox"/> T0</td> <td></td> <td>No evidence of primary tumor</td> </tr> <tr> <td><input type="checkbox"/> Tis</td> <td>*</td> <td>Carcinoma <i>in situ</i> (preinvasive carcinoma)</td> </tr> <tr> <td><input type="checkbox"/> T1a</td> <td>IA</td> <td>Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**</td> </tr> <tr> <td><input type="checkbox"/> T1b</td> <td>IB</td> <td>Lesions &gt;2 cm in size <b>or</b> any size with stromal invasion &gt;1.0 mm, confined to the vulva or perineum</td> </tr> <tr> <td><input type="checkbox"/> T2***</td> <td>II</td> <td>Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)</td> </tr> <tr> <td><input type="checkbox"/> T3****</td> <td>IVA</td> <td>Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,</td> </tr> </tbody> </table> <p style="font-size: small; margin-top: 10px;">* FIGO staging no longer includes Stage 0 (Tis).            ** The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.            *** FIGO uses the classification T2/T3. This is defined as T2 in TNM.            **** FIGO uses the classification T4. This is defined as T3 in TNM.</p>	TNM CATEGORY	FIGO STAGE	PRIMARY TUMOR (T)	<input type="checkbox"/> TX		Primary tumor cannot be assessed	<input type="checkbox"/> T0		No evidence of primary tumor	<input type="checkbox"/> Tis	*	Carcinoma <i>in situ</i> (preinvasive carcinoma)	<input type="checkbox"/> T1a	IA	Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**	<input type="checkbox"/> T1b	IB	Lesions >2 cm in size <b>or</b> any size with stromal invasion >1.0 mm, confined to the vulva or perineum	<input type="checkbox"/> T2***	II	Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)	<input type="checkbox"/> T3****	IVA	Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">PRIMARY TUMOR (T)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> TX</td> <td></td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td><input type="checkbox"/> T0</td> <td></td> <td>No evidence of primary tumor</td> </tr> <tr> <td><input type="checkbox"/> Tis</td> <td>*</td> <td>Carcinoma <i>in situ</i> (preinvasive carcinoma)</td> </tr> <tr> <td><input type="checkbox"/> T1a</td> <td>IA</td> <td>Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**</td> </tr> <tr> <td><input type="checkbox"/> T1b</td> <td>IB</td> <td>Lesions &gt;2 cm in size <b>or</b> any size with stromal invasion &gt;1.0 mm, confined to the vulva or perineum</td> </tr> <tr> <td><input type="checkbox"/> T2***</td> <td>II</td> <td>Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)</td> </tr> <tr> <td><input type="checkbox"/> T3****</td> <td>IVA</td> <td>Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,</td> </tr> </tbody> </table>	TNM CATEGORY	FIGO STAGE	PRIMARY TUMOR (T)	<input type="checkbox"/> TX		Primary tumor cannot be assessed	<input type="checkbox"/> T0		No evidence of primary tumor	<input type="checkbox"/> Tis	*	Carcinoma <i>in situ</i> (preinvasive carcinoma)	<input type="checkbox"/> T1a	IA	Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**	<input type="checkbox"/> T1b	IB	Lesions >2 cm in size <b>or</b> any size with stromal invasion >1.0 mm, confined to the vulva or perineum	<input type="checkbox"/> T2***	II	Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)	<input type="checkbox"/> T3****	IVA	Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,																		
TNM CATEGORY	FIGO STAGE	PRIMARY TUMOR (T)																																																																	
<input type="checkbox"/> TX		Primary tumor cannot be assessed																																																																	
<input type="checkbox"/> T0		No evidence of primary tumor																																																																	
<input type="checkbox"/> Tis	*	Carcinoma <i>in situ</i> (preinvasive carcinoma)																																																																	
<input type="checkbox"/> T1a	IA	Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**																																																																	
<input type="checkbox"/> T1b	IB	Lesions >2 cm in size <b>or</b> any size with stromal invasion >1.0 mm, confined to the vulva or perineum																																																																	
<input type="checkbox"/> T2***	II	Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)																																																																	
<input type="checkbox"/> T3****	IVA	Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,																																																																	
TNM CATEGORY	FIGO STAGE	PRIMARY TUMOR (T)																																																																	
<input type="checkbox"/> TX		Primary tumor cannot be assessed																																																																	
<input type="checkbox"/> T0		No evidence of primary tumor																																																																	
<input type="checkbox"/> Tis	*	Carcinoma <i>in situ</i> (preinvasive carcinoma)																																																																	
<input type="checkbox"/> T1a	IA	Lesions ? 2 cm in size, confined to the vulva or perineum and with stromal invasion ? 1.0 mm**																																																																	
<input type="checkbox"/> T1b	IB	Lesions >2 cm in size <b>or</b> any size with stromal invasion >1.0 mm, confined to the vulva or perineum																																																																	
<input type="checkbox"/> T2***	II	Tumor of any size with extension to adjacent perineal structures (Lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)																																																																	
<input type="checkbox"/> T3****	IVA	Tumor of any size with extension to any of the following: upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone,																																																																	
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">REGIONAL LYMPH NODES (N)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> NX</td> <td></td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td><input type="checkbox"/> N0</td> <td></td> <td>No regional lymph node metastasis</td> </tr> <tr> <td><input type="checkbox"/> N1</td> <td></td> <td>One or two regional lymph node with the following features</td> </tr> <tr> <td><input type="checkbox"/> N1a</td> <td>IIIA</td> <td>One or two lymph node metastasis each 5 mm or less</td> </tr> <tr> <td><input type="checkbox"/> N1b</td> <td>IIIA</td> <td>One lymph node metastases 5 mm or greater</td> </tr> <tr> <td><input type="checkbox"/> N2</td> <td>IIIB</td> <td>Regional lymph node metastasis with the following features:</td> </tr> <tr> <td><input type="checkbox"/> N2a</td> <td>IIIB</td> <td>Three or more lymph node metastases each less than 5 mm</td> </tr> <tr> <td><input type="checkbox"/> N2b</td> <td>IIIB</td> <td>Two or more lymph node metastases 5 mm or greater</td> </tr> <tr> <td><input type="checkbox"/> N2c</td> <td>IIIC</td> <td>Lymph node metastasis with extracapsular spread</td> </tr> <tr> <td><input type="checkbox"/> N3</td> <td>IVA</td> <td>Fixed or ulcerated regional lymph node metastasis</td> </tr> </tbody> </table> <p style="font-size: small; margin-top: 10px;">An effort should be made to describe the site and laterality of lymph node metastases.</p>	TNM CATEGORY	FIGO STAGE	REGIONAL LYMPH NODES (N)	<input type="checkbox"/> NX		Regional lymph nodes cannot be assessed	<input type="checkbox"/> N0		No regional lymph node metastasis	<input type="checkbox"/> N1		One or two regional lymph node with the following features	<input type="checkbox"/> N1a	IIIA	One or two lymph node metastasis each 5 mm or less	<input type="checkbox"/> N1b	IIIA	One lymph node metastases 5 mm or greater	<input type="checkbox"/> N2	IIIB	Regional lymph node metastasis with the following features:	<input type="checkbox"/> N2a	IIIB	Three or more lymph node metastases each less than 5 mm	<input type="checkbox"/> N2b	IIIB	Two or more lymph node metastases 5 mm or greater	<input type="checkbox"/> N2c	IIIC	Lymph node metastasis with extracapsular spread	<input type="checkbox"/> N3	IVA	Fixed or ulcerated regional lymph node metastasis	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">REGIONAL LYMPH NODES (N)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> NX</td> <td></td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td><input type="checkbox"/> N0</td> <td></td> <td>No regional lymph node metastasis</td> </tr> <tr> <td><input type="checkbox"/> N1</td> <td></td> <td>One or two regional lymph node with the following features</td> </tr> <tr> <td><input type="checkbox"/> N1a</td> <td>IIIA</td> <td>One or two lymph node metastasis each 5 mm or less</td> </tr> <tr> <td><input type="checkbox"/> N1b</td> <td>IIIA</td> <td>One lymph node metastases 5 mm or greater</td> </tr> <tr> <td><input type="checkbox"/> N2</td> <td>IIIB</td> <td>Regional lymph node metastasis with the following features:</td> </tr> <tr> <td><input type="checkbox"/> N2a</td> <td>IIIB</td> <td>Three or more lymph node metastases each less than 5 mm</td> </tr> <tr> <td><input type="checkbox"/> N2b</td> <td>IIIB</td> <td>Two or more lymph node metastases 5 mm or greater</td> </tr> <tr> <td><input type="checkbox"/> N2c</td> <td>IIIC</td> <td>Lymph node metastasis with extracapsular spread</td> </tr> <tr> <td><input type="checkbox"/> N3</td> <td>IVA</td> <td>Fixed or ulcerated regional lymph node metastasis</td> </tr> </tbody> </table>	TNM CATEGORY	FIGO STAGE	REGIONAL LYMPH NODES (N)	<input type="checkbox"/> NX		Regional lymph nodes cannot be assessed	<input type="checkbox"/> N0		No regional lymph node metastasis	<input type="checkbox"/> N1		One or two regional lymph node with the following features	<input type="checkbox"/> N1a	IIIA	One or two lymph node metastasis each 5 mm or less	<input type="checkbox"/> N1b	IIIA	One lymph node metastases 5 mm or greater	<input type="checkbox"/> N2	IIIB	Regional lymph node metastasis with the following features:	<input type="checkbox"/> N2a	IIIB	Three or more lymph node metastases each less than 5 mm	<input type="checkbox"/> N2b	IIIB	Two or more lymph node metastases 5 mm or greater	<input type="checkbox"/> N2c	IIIC	Lymph node metastasis with extracapsular spread	<input type="checkbox"/> N3	IVA	Fixed or ulcerated regional lymph node metastasis
TNM CATEGORY	FIGO STAGE	REGIONAL LYMPH NODES (N)																																																																	
<input type="checkbox"/> NX		Regional lymph nodes cannot be assessed																																																																	
<input type="checkbox"/> N0		No regional lymph node metastasis																																																																	
<input type="checkbox"/> N1		One or two regional lymph node with the following features																																																																	
<input type="checkbox"/> N1a	IIIA	One or two lymph node metastasis each 5 mm or less																																																																	
<input type="checkbox"/> N1b	IIIA	One lymph node metastases 5 mm or greater																																																																	
<input type="checkbox"/> N2	IIIB	Regional lymph node metastasis with the following features:																																																																	
<input type="checkbox"/> N2a	IIIB	Three or more lymph node metastases each less than 5 mm																																																																	
<input type="checkbox"/> N2b	IIIB	Two or more lymph node metastases 5 mm or greater																																																																	
<input type="checkbox"/> N2c	IIIC	Lymph node metastasis with extracapsular spread																																																																	
<input type="checkbox"/> N3	IVA	Fixed or ulcerated regional lymph node metastasis																																																																	
TNM CATEGORY	FIGO STAGE	REGIONAL LYMPH NODES (N)																																																																	
<input type="checkbox"/> NX		Regional lymph nodes cannot be assessed																																																																	
<input type="checkbox"/> N0		No regional lymph node metastasis																																																																	
<input type="checkbox"/> N1		One or two regional lymph node with the following features																																																																	
<input type="checkbox"/> N1a	IIIA	One or two lymph node metastasis each 5 mm or less																																																																	
<input type="checkbox"/> N1b	IIIA	One lymph node metastases 5 mm or greater																																																																	
<input type="checkbox"/> N2	IIIB	Regional lymph node metastasis with the following features:																																																																	
<input type="checkbox"/> N2a	IIIB	Three or more lymph node metastases each less than 5 mm																																																																	
<input type="checkbox"/> N2b	IIIB	Two or more lymph node metastases 5 mm or greater																																																																	
<input type="checkbox"/> N2c	IIIC	Lymph node metastasis with extracapsular spread																																																																	
<input type="checkbox"/> N3	IVA	Fixed or ulcerated regional lymph node metastasis																																																																	
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">DISTANT METASTASIS (M)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> M0</td> <td></td> <td>No distant metastasis (no pathologic M0; use clinical M to complete stage group)</td> </tr> <tr> <td><input type="checkbox"/> M1</td> <td>IVB</td> <td>Distant metastasis (including pelvic lymph node metastasis)</td> </tr> </tbody> </table>	TNM CATEGORY	FIGO STAGE	DISTANT METASTASIS (M)	<input type="checkbox"/> M0		No distant metastasis (no pathologic M0; use clinical M to complete stage group)	<input type="checkbox"/> M1	IVB	Distant metastasis (including pelvic lymph node metastasis)	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">TNM CATEGORY</th> <th style="width: 15%;">FIGO STAGE</th> <th style="width: 70%;">DISTANT METASTASIS (M)</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> M0</td> <td></td> <td>No distant metastasis (no pathologic M0; use clinical M to complete stage group)</td> </tr> <tr> <td><input type="checkbox"/> M1</td> <td>IVB</td> <td>Distant metastasis (including pelvic lymph node metastasis)</td> </tr> </tbody> </table>	TNM CATEGORY	FIGO STAGE	DISTANT METASTASIS (M)	<input type="checkbox"/> M0		No distant metastasis (no pathologic M0; use clinical M to complete stage group)	<input type="checkbox"/> M1	IVB	Distant metastasis (including pelvic lymph node metastasis)																																																
TNM CATEGORY	FIGO STAGE	DISTANT METASTASIS (M)																																																																	
<input type="checkbox"/> M0		No distant metastasis (no pathologic M0; use clinical M to complete stage group)																																																																	
<input type="checkbox"/> M1	IVB	Distant metastasis (including pelvic lymph node metastasis)																																																																	
TNM CATEGORY	FIGO STAGE	DISTANT METASTASIS (M)																																																																	
<input type="checkbox"/> M0		No distant metastasis (no pathologic M0; use clinical M to complete stage group)																																																																	
<input type="checkbox"/> M1	IVB	Distant metastasis (including pelvic lymph node metastasis)																																																																	

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION
-----------------------	--------------------------

(continued on next page)

# VULVA STAGING FORM

## ANATOMIC STAGE • PROGNOSTIC GROUPS

CLINICAL				PATHOLOGIC			
GROUP	T	N	M	GROUP	T	N	M
<input type="checkbox"/> 0*	Tis	N0	M0	<input type="checkbox"/> 0*	Tis	N0	M0
<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> I	T	N0	M0
<input type="checkbox"/> IA	T1a	N0	M0	<input type="checkbox"/> IA	T1a	N0	M0
<input type="checkbox"/> IB	T1b	N0	M0	<input type="checkbox"/> IB	T1b	N0	M0
<input type="checkbox"/> II	T2	N0	M0	<input type="checkbox"/> II	T2	N0	M0
<input type="checkbox"/> IIIA	T1, T2	N1a, N1b	M0	<input type="checkbox"/> IIIA	T1, T2	N1a, N1b	M0
<input type="checkbox"/> IIIB	T1, T2	N2a, N2b	M0	<input type="checkbox"/> IIIB	T1, T2	N2a, N2b	M0
<input type="checkbox"/> IIIC	T1, T2	N2c	M0	<input type="checkbox"/> IIIC	T1, T2	N2c	M0
<input type="checkbox"/> IVA	T1, T2	N3	M0	<input type="checkbox"/> IVA	T1, T2	N3	M0
	T3	Any N	M0		T3	Any N	M0
<input type="checkbox"/> IVB	Any T	Any N	M1	<input type="checkbox"/> IVB	Any T	Any N	M1

\*FIGO no longer includes Stage 0 (Tis).

Stage unknown

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)	General Notes:
<p><b>REQUIRED FOR STAGING:</b> None</p> <p><b>CLINICALLY SIGNIFICANT:</b></p> <p>FIGO Stage: _____</p> <p>Pelvic nodal status and method of assessment: _____</p> <p>Femoral-Inguinal nodal status and method of assessment: _____</p>	<p>For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.</p> <p><b>m suffix</b> indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.</p> <p><b>y prefix</b> indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.</p> <p><b>r prefix</b> indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.</p> <p><b>a prefix</b> designates the stage determined at autopsy: aTNM.</p>

<p><b>Histologic Grade (G)</b> (also known as overall grade)</p> <table style="width: 100%;"> <thead> <tr> <th style="text-align: left;">Grading system</th> <th style="text-align: left;">Grade</th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> 2 grade system</td> <td><input type="checkbox"/> Grade I or 1</td> </tr> <tr> <td><input type="checkbox"/> 3 grade system</td> <td><input type="checkbox"/> Grade II or 2</td> </tr> <tr> <td><input type="checkbox"/> 4 grade system</td> <td><input type="checkbox"/> Grade III or 3</td> </tr> <tr> <td><input type="checkbox"/> No 2, 3, or 4 grade system is available</td> <td><input type="checkbox"/> Grade IV or 4</td> </tr> </tbody> </table>		Grading system	Grade	<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1	<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2	<input type="checkbox"/> 4 grade system	<input type="checkbox"/> Grade III or 3	<input type="checkbox"/> No 2, 3, or 4 grade system is available	<input type="checkbox"/> Grade IV or 4
Grading system	Grade										
<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1										
<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2										
<input type="checkbox"/> 4 grade system	<input type="checkbox"/> Grade III or 3										
<input type="checkbox"/> No 2, 3, or 4 grade system is available	<input type="checkbox"/> Grade IV or 4										
<p><b>ADDITIONAL DESCRIPTORS</b></p> <p><b>Lymphatic Vessel Invasion (L) and Venous Invasion (V)</b> have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.</p> <p><input type="checkbox"/> Lymph-Vascular Invasion Not Present (absent)/Not Identified</p> <p><input type="checkbox"/> Lymph-Vascular Invasion Present/Identified</p> <p><input type="checkbox"/> Not Applicable</p> <p><input type="checkbox"/> Unknown/Indeterminate</p>											

<p>HOSPITAL NAME/ADDRESS</p>	<p>PATIENT NAME/INFORMATION</p>
------------------------------	---------------------------------

(continued from previous page)

## VULVA STAGING FORM

**Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

**General Notes (continued):**

**surgical margins** is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

**neoadjuvant treatment** is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

Clinical stage was used in treatment planning (describe): \_\_\_\_\_

National guidelines were used in treatment planning     NCCN     Other (describe): \_\_\_\_\_

\_\_\_\_\_  
Physician signature

\_\_\_\_\_  
Date/Time

HOSPITAL NAME/ADDRESS






PATIENT NAME/INFORMATION

*(continued on next page)*

# VULVA STAGING FORM

## Illustration

Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION

(continued from previous page)